CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

When Sarah told her elderly mother about what she had found, she was horrified to hear that James had also been sexually ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

GSK’s blood cancer drug Blenrep has been reapproved by the EU medicines regulator after it was removed from sale in 2023 because a trial failed to show it was superior to other treatments.